292 related articles for article (PubMed ID: 17391337)
1. Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group.
Koistinen P; Räty R; Itälä M; Jantunen E; Koivunen E; Nousiainen T; Pelliniemi TT; Remes K; Ruutu T; Savolainen ER; Siitonen T; Silvennoinen R; Volin L; Elonen E;
Eur J Haematol; 2007 Jun; 78(6):477-86. PubMed ID: 17391337
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
3. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
4. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
5. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
6. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
7. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
[TBL] [Abstract][Full Text] [Related]
8. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
[TBL] [Abstract][Full Text] [Related]
9. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
[TBL] [Abstract][Full Text] [Related]
10. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
11. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
12. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
Oriol A; Ribera JM; Esteve J; Guàrdia R; Brunet S; Bueno J; Pedro C; Llorente A; Tormo M; Besalduch J; Sánchez JM; Batlle M; Vivancos P; Carreras E; Vilà JM; Julià A; Sierra J; Montserrat E; Feliu E;
Haematologica; 2004 Jul; 89(7):791-800. PubMed ID: 15257930
[TBL] [Abstract][Full Text] [Related]
14. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
[TBL] [Abstract][Full Text] [Related]
15. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia.
Bloomfield CD; Shuma C; Regal L; Philip PP; Hossfeld DK; Hagemeijer AM; Garson OM; Peterson BA; Sakurai M; Alimena G; Berger R; Rowley JD; Ruutu T; Mitelman F; Dewald GW; Swansbury J
Cancer; 1997 Dec; 80(11 Suppl):2191-8. PubMed ID: 9395033
[TBL] [Abstract][Full Text] [Related]
17. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy in childhood acute myeloid leukemia.
Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
[TBL] [Abstract][Full Text] [Related]
19. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
Knipp S; Hildebrand B; Kündgen A; Giagounidis A; Kobbe G; Haas R; Aul C; Gattermann N; Germing U
Cancer; 2007 Jul; 110(2):345-52. PubMed ID: 17559141
[TBL] [Abstract][Full Text] [Related]
20. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
